A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
Author:
Hart Delaney E1, Gallagher Jason C2, Puzniak Laura A3, Hirsch Elizabeth B1, Bandali Aiman, Beaulac Kirthana R, Bias Tiffany E, Biason Kenneth, Bland Christopher M, Boeser Kimberly, Chaudhry Saira, Claeys Kimberly C, Cubillos Ashley L, Dionne Brandon, Dixit Deepali, El-Beyrouty Claudine, Elabor Abdulrahman, Gancher Elizabeth, Guo Yi, Harrington Nicole, Heil Emily L, Hiles Jon, Jones Bruce M, King Madeline A, Lu Xiaoning, Mahoney Monica V, McCoy Dorothy, McCreary Erin K, Molnar Esther, Piche Ashley, Raddatz Janet K, Richards Lynette, Saraiya Nidhi, Satlin Michael J, Suh Jin, Virk Abinash, Vyas Nikunj M, Yu Daohai,
Affiliation:
1. University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA 2. Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA 3. Merck & Co., Inc., Kenilworth, New Jersey, USA
Abstract
Abstract
Background
Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa.
Methods
This was a 14-center retrospective cohort study of adult immunocompromised inpatients treated for ≥24 hours with C/T for MDR P. aeruginosa infections. Patients were defined as immunocompromised if they had a history of previous solid organ transplant (SOT), disease that increased susceptibility to infection, or received immunosuppressive therapies. The primary outcomes were all-cause 30-day mortality and clinical cure.
Results
Sixty-nine patients were included; 84% received immunosuppressive agents, 68% had a history of SOT, and 29% had diseases increasing susceptibility to infection. The mean patient age was 57 ± 14 years, and the median (interquartile range) patient Acute Physiology and Chronic Health Evaluation II and Charlson Comorbidity Index scores were 18 (13) and 5 (4), respectively, with 46% receiving intensive care unit care at C/T initiation. The most frequent infection sources were respiratory (56%) and wound (11%). All-cause 30-day mortality was 19% (n = 13), with clinical cure achieved in 47 (68%) patients. Clinical cure was numerically higher (75% vs 30%) in pneumonia patients who received 3-g pneumonia regimens vs 1.5-g regimens.
Conclusions
Of 69 immunocompromised patients treated with C/T for MDR P. aeruginosa, clinical cure was achieved in 68% and mortality was 19%, consistent with other reports on a cross-section of patient populations. C/T represents a promising agent for treatment of P. aeruginosa resistant to traditional antipseudomonal agents in this high-risk population.
Funder
Merck Sharp and Dohme Merck & Co., Inc.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Oncology
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|